| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2005 | US20050038057 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione; utility in treatment of a variety of sex-hormone related conditions in both men and women |
| 02/17/2005 | US20050038054 Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| 02/17/2005 | US20050038053 Cyclohexylthiophenepyrimidinone, cyclohexylpyrrolylpyrimidinone or cyclohexylfuranylpyrimidinone compounds for use in the treatment of a steroid hormone dependent diseases; inhibitor of 17 beta -hydroxysteroid dehydrogenase enzymes |
| 02/17/2005 | US20050038051 Novel molecules for regulating cell death |
| 02/17/2005 | US20050038050 Therapeutic treatment of autoimmune disease, transplant rejection, rheumatoid arthritis, by administering 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline |
| 02/17/2005 | US20050038049 Prevention, therapy of disease sensitivie to kinase; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis; psychological disorders; schizophrenia |
| 02/17/2005 | US20050038048 Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases |
| 02/17/2005 | US20050038046 Synergistic enhancement of cognitive ability |
| 02/17/2005 | US20050038045 A2B adenosine receptor antagonists |
| 02/17/2005 | US20050038044 For drug resistance disease; side effect reduction; antiinflammatory agents; autoimmune disease |
| 02/17/2005 | US20050038042 Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders |
| 02/17/2005 | US20050038039 Formulations |
| 02/17/2005 | US20050038037 N-(naphth-2-ylaminocarbonylacetyl)- or N-(naphth-2-ylcarbonylamino- acetyl)- piperazine derivatives, e.g., 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]aminonaphthalene; useful as antithrombotic agents |
| 02/17/2005 | US20050038036 Treatment of bipolar disorders and associated symptoms |
| 02/17/2005 | US20050038034 Analgesics; neurodegenerative disorders; multiple sclerosis; Parkinson's disease; neuropathic pain |
| 02/17/2005 | US20050038031 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
| 02/17/2005 | US20050038029 Transferring, releasing nitric oxide; side effect reduction; using a compound containing nitrosos group |
| 02/17/2005 | US20050038028 Hydroxyethylene compounds with asp2 inhibitory activity |
| 02/17/2005 | US20050038027 Melanocortin-4 receptor agonists; obesity, type II diabetes; such as N-(2-(2-(2,4-dichlorophenyl)ethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl) -3-methyl-N'-(2,6,6-trimethylbicyclo(3.1.1)hept-3yl)piperazine-1-carboximidamide |
| 02/17/2005 | US20050038025 Thioarabinofuranosyl compounds and use thereof |
| 02/17/2005 | US20050038023 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 02/17/2005 | US20050038022 Using a benzimidazole carbamate compound in lipid carrier; antitumor agents |
| 02/17/2005 | US20050038019 Hydroxy substituted amides for the treatment of alzheimer's disease |
| 02/17/2005 | US20050038018 Meloxicam compositions |
| 02/17/2005 | US20050038017 Synergistic mixture of adenosine antagonist and diuretics |
| 02/17/2005 | US20050038016 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists |
| 02/17/2005 | US20050038015 Partial dopamine-D 2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity |
| 02/17/2005 | US20050038014 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 02/17/2005 | US20050038013 Treatment of sleep disorders with cholinesterase inhibitors |
| 02/17/2005 | US20050038010 Substituted heterocyclic compounds and methods of use |
| 02/17/2005 | US20050038009 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- alpha -[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine |
| 02/17/2005 | US20050038008 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 02/17/2005 | US20050038007 Adjust solubility; immediate release of HMG-COA reductase inhibitor and sustained release of cholesteryl ester transfer protein; anticholesterol agents |
| 02/17/2005 | US20050038006 Administering combination of estrogen and progestogen to female of childbearing age for twenty-one days; controlling dosage cycles |
| 02/17/2005 | US20050038005 Controlling dosage cycles; |
| 02/17/2005 | US20050038004 Synergistic mixture of steroid and anticholinergic agent; respiratory system disorders |
| 02/17/2005 | US20050038002 Bactericides; antitumor agents; moderators of gene expression; viricides; parasiticides; malaria therapy |
| 02/17/2005 | US20050038001 Transdiscal administration of cycline compounds |
| 02/17/2005 | US20050038000 Anticonvulsants; Alzheimer's disease; antidiabetic agents; primary amine compound containing aromatic ring |
| 02/17/2005 | US20050037999 Antiproliferative agents |
| 02/17/2005 | US20050037998 Enhancement of magnesium uptake in mammals |
| 02/17/2005 | US20050037996 Controlling temperature and pH while complexing |
| 02/17/2005 | US20050037995 Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
| 02/17/2005 | US20050037994 Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same |
| 02/17/2005 | US20050037993 Bulking agents as satiety agents |
| 02/17/2005 | US20050037992 Composition and method for treating neurological disorders |
| 02/17/2005 | US20050037991 Synthesis and compositions of 2'-terminator nucleotides |
| 02/17/2005 | US20050037990 Disubstituted 7,9-guanines halides as telomerase inhibitors |
| 02/17/2005 | US20050037985 Administering CpG oligonucleotide to patient infected with human immunodeficiency virus |
| 02/17/2005 | US20050037984 Administering protein kinase C activator |
| 02/17/2005 | US20050037983 Compositions and methods for the treatment of depression and other affective disorders |
| 02/17/2005 | US20050037981 Substituted indole-O-glucosides |
| 02/17/2005 | US20050037980 Substituted fused heterocyclic C-glycosides |
| 02/17/2005 | US20050037979 Tannate compositions and methods of use |
| 02/17/2005 | US20050037977 Compounds for treating tumors |
| 02/17/2005 | US20050037976 Hematopoietic stimulation |
| 02/17/2005 | US20050037975 Nervous system disorders; Alzheimer's disease |
| 02/17/2005 | US20050037958 Therapy for kidney and congestive heart failure; nephrotic syndrome; pulmonary edema; hypotensive agents; adjust urine flow |
| 02/17/2005 | US20050037955 Bactericides; fungicides; isolated polypeptides; inflammatory bowel disorders; infections |
| 02/17/2005 | US20050037953 Aspartyl protease inhibitor; antimalaria agents |
| 02/17/2005 | US20050037947 Bioavailability; controlling dosage ; chimera protein coupling to immunoglobulin |
| 02/17/2005 | US20050037506 Methods of determining film thicknesses for an aerosol delivery article |
| 02/17/2005 | US20050037494 Using antisense agents to reduce and/or prevention genic expression associated with cardi-vascular complications; gene therapy |
| 02/17/2005 | US20050037462 Expression vector comprising nucleotide sequences coding g protein for use in generating immunoglobulins for use in prevention, treatment and diagnosis of cell proliferative disorders |
| 02/17/2005 | US20050037404 Methods of modulating drug clearance mechanisms by altering SXR activity |
| 02/17/2005 | US20050037403 Immunomodulatory oligonucleotides |
| 02/17/2005 | US20050037133 On site polymerization of vinylidenefluoride and hexafluoropropolyene to desired thickness, dip coating stent and/or catheter having complex configuration into latex emulsion containing medication; reducing material loss; customized variable dosaging |
| 02/17/2005 | US20050037102 Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| 02/17/2005 | US20050037100 Utilization of extracts from iris plants, cimicifuga racemose and tectorigenin as an estrogen-like organ-selective medicament without uterotropic |
| 02/17/2005 | US20050037099 Such as isoflavones, phytoestrogens, sitosterols and saponins from soy for use in a dermatological or cosmetic preparation; hydrolysis in acidic solution, adding water to precipitate, followed by solvent extraction steps in alcohol and organic solvent |
| 02/17/2005 | US20050037097 Pyruvate enriched onion extract |
| 02/17/2005 | US20050037095 Compositions enriched in anthocyanins |
| 02/17/2005 | US20050037094 Extract of raw herbs of Radix Salviae Miltorrhizae, Panax Notoginseng and Borneol |
| 02/17/2005 | US20050037093 Treatment of nail infections with no |
| 02/17/2005 | US20050037091 Composition comprising paracetamol and a bitterness masking component |
| 02/17/2005 | US20050037090 Selected from Vitaxin, exemestane, anastrozole, letrozole, thiotepa, SU-5416, capecitabine, tamoxifen, raloxifene, fluoxymesterone, megestrol, toremifene, goserelin, ornithine decarboxylase inhibitors such as eflornithine, bisphosphonates and sulindac sulfone |
| 02/17/2005 | US20050037089 Administering a bone remodeling agent such as parathyroid hormone and a dietary supplement comprising calcium and phosphorus |
| 02/17/2005 | US20050037087 Microcapsular composition comprising core, including at least one active ingredient in combination with an oil or mixture of oils, wherein oils alone or in combination with active ingredient have specific gravity higher than that of water; microcapsules can be easily isolated by precipitation |
| 02/17/2005 | US20050037085 Microencapsulated DNA for vaccination and gene therapy |
| 02/17/2005 | US20050037083 Activating a water insoluble drug in aqueous solution; freeze drying; intravenous injection; sonicating evaporation |
| 02/17/2005 | US20050037081 Novel formulation |
| 02/17/2005 | US20050037077 Absorption in upper part of gastrointestinal system; microcapsules coated with hydrophilic polymer such as Eudragit |
| 02/17/2005 | US20050037074 Treating adrenal dysfunction in a patient by administering a pharmaceutically effective amount of a combined glucocorticoid such as hydrocortisone and a delivery vehicle, wherein delivery vehicle provides for delayed and sustained release of glucorticoid; congenital adrenal hyperplasia |
| 02/17/2005 | US20050037072 Pharmaceutical compositions for rectal and vaginal administration |
| 02/17/2005 | US20050037069 Solid and stable creatine/citric acid composition(s) and compositions carbohydrate(s) or hydrates thereof, method for the production and use thereof |
| 02/17/2005 | US20050037068 Solid, stabilized, prompt-and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs |
| 02/17/2005 | US20050037067 3,7-Diazabicyclo [3.3.1]formulations as anti-arrhythmic compounds |
| 02/17/2005 | US20050037066 Formulation and manufacturing process for Coenzyme Q10 soft gel capsules |
| 02/17/2005 | US20050037065 Fatty acids from both plant and animal sources and methods for minimizing unpleasant taste, regurgitation, gastroesophageal reflux, dyspepsia, nausea, or difficulty in swallowing or ingesting; for pregnant or lactating women |
| 02/17/2005 | US20050037063 Combined therapies |
| 02/17/2005 | US20050037062 In combination with another active ingredient capable of potentiating the effects of the azetidine compound in a system comprising a phospholipid, or a combination of Miglyol, capriol and cremophor; for preparing chemically and physically stable pharmaceutical compositions |
| 02/17/2005 | US20050037060 topical mixture of minoxidil or salts, solubilizers, solvents and cosolvents, used for the treatment of alopecia |
| 02/17/2005 | US20050037049 use of benzyl ester of hyaluronic acid and/or derivatives, in association with other biopolymers and antitumor agents to fill cavities when the tumor have been surgically removed |
| 02/17/2005 | US20050037040 cosmetics used for treatment of skin disorders |
| 02/17/2005 | US20050037039 Composition for treatment of tinea pedis and method of use |
| 02/17/2005 | US20050037035 comprising sphingoids used as cosmetic for topical application with animals having fur covered skins for maintaining and/or repairing the keratoseborrheaic condition of the skin and/or fur; skin disorders |
| 02/17/2005 | US20050037034 mixture of carriers, abrasive particles and antiacne agents; exfoliation of human skins using applicators having handles and motors |
| 02/17/2005 | US20050037033 microbiocides used for preventing of sexually transmitted infections comprising ciclopirox olamine and carriers |
| 02/17/2005 | US20050037030 Stable topical formulation of clarithromycin |
| 02/17/2005 | US20050037025 Caffeine-free and tannin-free mixtures; anxiolytic and antiinflammatory agents, antidepressants, analgesics; tension, fatigue, headaches, psychological disorders |